MY01

MY01 is an innovative force in the intersection of Biotechnology, Medical Devices, and Autonomous and Sensor Tech, founded in 2015. Headquartered in Canada, the company is revolutionizing the detection and diagnosis of Compartment Syndrome (CS), a critical medical condition occurring post-trauma.

The company’s groundbreaking product provides trauma teams with accurate real-time data via a single-use device, greatly enhancing clinical decision-making and addressing inefficiencies in current CS diagnostics. By tapping into the proven link between increased intramuscular pressures and ACS, MY01 is poised to significantly reduce healthcare expenditures—currently over $2.25 billion annually in the U.S.

To date, MY01 has not publicly disclosed recent funding rounds or investor partnerships, yet its technological pedigree traces back to engineering by NXTSENS. This positions MY01 as a promising investment opportunity in a rapidly advancing medical field.